Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of September 13, 2026, GILD trades at $143.94 with a market cap of $178.21B and a P/E ratio of -55.36. GILD moved -0.73% today. Year to date, GILD is +17.09%; over the trailing twelve months it is +21.94%. Its 52-week range spans $91.84 to $157.29. Analyst consensus is strong buy with an average price target of $158.05. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
21 analysts cover GILD: 0 strong buy, 17 buy, 4 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $158.05.
| Metric | Value |
|---|---|
| Price | $143.94 |
| Market Cap | $178.21B |
| P/E Ratio | -55.36 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $91.84 |
| Volume | 2.57M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
21 analysts cover GILD: 0 strong buy, 17 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $158.05.